Abstract
Synthesis de novo, acquisition by salvage and interconversion of purines and pyrimidines represent the fundamental requirements for their eventual assembly into nucleic acids as nucleotides and the deployment of their derivatives in other biochemical pathways. A small number of drugs targeted to nucleotide metabolism, by virtue of their effect on folate biosynthesis and recycling, have been successfully used against apicomplexan parasites such as Plasmodium and Toxoplasma for many years, although resistance is now a major problem in the prevention and treatment of malaria. Many targets not involving folate metabolism have also been explored at the experimental level. However, the unravelling of the genome sequences of these eukaryotic unicellular organisms, together with increasingly sophisticated molecular analyses, opens up possibilities of introducing new drugs that could interfere with these processes. This review examines the status of established drugs of this type and the potential for further exploiting the vulnerability of apicomplexan human pathogens to inhibition of this key area of metabolism
Keywords: Plasmodium, Toxoplasma, Cryptosporidium, nucleotide biosynthesis, salvage pathways, drug resistance, drug targets, folate metabolism
Current Drug Targets
Title: Targeting Purine and Pyrimidine Metabolism in Human Apicomplexan Parasites
Volume: 8 Issue: 1
Author(s): John E. Hyde
Affiliation:
Keywords: Plasmodium, Toxoplasma, Cryptosporidium, nucleotide biosynthesis, salvage pathways, drug resistance, drug targets, folate metabolism
Abstract: Synthesis de novo, acquisition by salvage and interconversion of purines and pyrimidines represent the fundamental requirements for their eventual assembly into nucleic acids as nucleotides and the deployment of their derivatives in other biochemical pathways. A small number of drugs targeted to nucleotide metabolism, by virtue of their effect on folate biosynthesis and recycling, have been successfully used against apicomplexan parasites such as Plasmodium and Toxoplasma for many years, although resistance is now a major problem in the prevention and treatment of malaria. Many targets not involving folate metabolism have also been explored at the experimental level. However, the unravelling of the genome sequences of these eukaryotic unicellular organisms, together with increasingly sophisticated molecular analyses, opens up possibilities of introducing new drugs that could interfere with these processes. This review examines the status of established drugs of this type and the potential for further exploiting the vulnerability of apicomplexan human pathogens to inhibition of this key area of metabolism
Export Options
About this article
Cite this article as:
Hyde E. John, Targeting Purine and Pyrimidine Metabolism in Human Apicomplexan Parasites, Current Drug Targets 2007; 8 (1) . https://dx.doi.org/10.2174/138945007779315524
DOI https://dx.doi.org/10.2174/138945007779315524 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
RNA Molecules in the Treatment of Human Diseases
Messenger and non-coding RNAs, including long and small transcripts, are mediators of gene expression. Gene expression at the RNA level shows significant aberrations in human diseases, including cancer, leukemia, lymphoma, cardiovascular diseases, and neurological disorders. Human transcripts serve either as biomarkers of diagnosis, prognosis, prediction of treatment response and/or therapy ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Exposure to Perinatal Infections and Bipolar Disorder: A Systematic Review
Current Molecular Medicine Update on ICOS: A Possible Target for Turning-Off Autoimmunity
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Protein Conformational Diseases: From Mechanisms to Drug Designs
Current Drug Discovery Technologies Virus-Based RNA Silencing Agents and Virus-Derived Expression Vectors as Gene Therapy Vehicles
Recent Patents on Biotechnology Altering the Tropism of Lentiviral Vectors through Pseudotyping
Current Gene Therapy Vaccine Development for Potential Bioterrorism Agents
Current Drug Targets - Infectious Disorders Chronic Progressive Multiple Sclerosis – Pathogenesis of Neurodegeneration and Therapeutic Strategies
Current Neuropharmacology Defining and Regulating Acute Inflammatory Lesion Formation during the Pathogenesis of Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis
CNS & Neurological Disorders - Drug Targets Specific Roles of NMDA Receptor Subunits in Mental Disorders
Current Molecular Medicine <i>In Silico</i> Analysis of Drug Repurposing Strategy for the Identification of Potential NS3 Helicase Inhibitors Against Zika Virus
Current Chinese Science Targeting Tumor Necrosis Factor Alpha for Alzheimer’s Disease
Current Alzheimer Research How to Manage the Infectious Risk under Anti-TNF in Inflammatory Bowel Disease
Current Drug Targets Immunology and Epilepsy: Clinical and Experimental Evidence
Current Immunology Reviews (Discontinued) Commentary: (Research Highlights Inflammation, Demyelination and Neurodegeneration: Risky Buddies in Multiple Sclerosis)
CNS & Neurological Disorders - Drug Targets Promises of Nanotechnology for Drug Delivery to Brain in Neurodegenerative Diseases
Current Nanoscience T2/FLAIR Hyperintensity in Mesial Temporal Lobe: Challenging Differential Diagnosis
Current Medical Imaging Advances in Oncolytic Virus Therapy for Glioma
Recent Patents on CNS Drug Discovery (Discontinued) Recent Patents on Alphavirus Protein Expression and Vector Production
Recent Patents on Biotechnology Inhibitions of Positive-Sense (ss) RNA Viruses RNA-Dependent RNA Polymerases
Current Enzyme Inhibition Regulatory T Cells in Central Nervous System: in Health and Disease
Central Nervous System Agents in Medicinal Chemistry